Dosage de l'homocystéine totale chez une cohorte de diabétiques de type 2

Otmane, Amel; Makrelouf, Mohamed; Bouchama, Rym; Boucelma, M.; Berrah, A.; Zenati, Akila

doi:10.1016/s1773-035x(07)80418-7

Cited by 4 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed such studies have reported the effect of diabetes treatment on the tHcy levels. Otmane and colleagues17 found that tHcy levels were higher in patients treated with sulfonamide than those treated with metformin. These results are in contrast with those found by Sahin and colleagues18 who demonstrated that metformin in type 2 diabetes increases Hcy levels, whereas rosiglitazone decreases Hcy level in the same time period.…”

Section: Discussionmentioning

confidence: 99%

Effect of lipopenic and hypotensive treatment on homocysteine levels in type 2 diabetics

Oudi¹

2010

VHRM

View full text Add to dashboard Cite

Aim:Evaluate the effect of lipopenic and hypotensive treatment on homocysteine levels.Methods:We recruited 145 type 2 diabetics and 130 control subjects. Thirty-seven diabetics had no complications, 54 had microvascular complications and 54 had macrovascular complications. We determined the parameters homocysteine of lipid, vitamin B12, triglycerides, and folates for all subjects. Associated treatments used one or more of the following drugs, statin, fibrate, angiotensin-converting enzyme inhibitor and beta-blockers.Results:Hyperhomocysteinemia was present in 35.6% of patients. Diabetics had elevated serum levels of triglycerides (P < 0.001), homocysteine (P < 0.01), folates (P < 0.01) and vitamin B12 (P < 0.001). A strong association was found between type 2 diabetes and hyperhomocysteinemia (P < 0.001). Diabetics with associated treatment had elevated homocysteine, vitamin B12 and folate levels when compared to diabetes-free controls. For diabetics with macrovascular complications, we found significant differences in homocysteine (P = 0.010) and folate (P = 0.014) between those taking associated drugs and those who did not. For diabetics with microvascular complications, a significant difference was found in folate only (P = 0.012).Conclusion:Drugs used for hypertension and hyperlipidemia may have an effect on homocysteine levels, for this reason the interaction between drug action and homocysteine levels should be taken into consideration.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of lipopenic and hypotensive treatment on homocysteine levels in type 2 diabetics

Oudi¹

2010

VHRM

View full text Add to dashboard Cite

show abstract

“…Some authors pointed out that HHcy is not the sole consequence of dysglycemia, but is also linked to other risk factors associated with T2D complications/comorbidities, although this was not a generalized opinion [23].…”

Section: Discussionmentioning

confidence: 99%

Hyperhomocysteinemia: Risk Factors and Faster Onset of Degenerative Complications of Type 2 Diabetes in Brazzaville

Russelh,

Bouenizabila,

Ongoth

et al. 2023

JDM

View full text Add to dashboard Cite

Background: Type 2 diabetes (T2D) remains a major global public health problem. This complex metabolic disorder can lead to various complications, including cardiovascular diseases (leading cause of death) in T2D. Among the biochemical markers associated with increased risk for cardiovascular disease, homocysteine is currently one of the predictive markers under evaluation. We investigate the link between hyperhomocysteinemia and diabetes complications in DT2 population in Brazzaville. Methodology: We conducted a cross-sectional analytical study, from October to December 2022. One hundred and fifty participants were included, 100 patients T2D (34 with complications, 33 with comorbidities, 33 without), and 50 patients controls. Sociodemographic and clinical characteristics were collected. Homocysteine (Hcy) serum levels were measured using Sandwich ELISA method. Results: Study population was composed of 50% males and 50% females with sex ratio of 1; mean age was 52.2 ± 10.8 years (30 -83). The prevalence of hyperhomocysteinemia (HHcy) was 36% (20% moderate Hcy, 15% intermediate and 1% severe). Mean Hcy con-How to cite this paper: Russelh, I.

show abstract

“…L'hyperhomocystéinémie représente aussi un facteur de risque cardiovasculaire et thromboembolique [4]. Une élévation de l'homocystéine (Hcy) plasmatique est due essentiellement à des facteurs génétiques ou nutritionnels [5], mais peut également résulter d'une altération de la fonction rénale [6].…”

Section: Introductionunclassified

Relation entre l’homocystéine et la créatinine sanguines chez des sujets atteints de syndrome métabolique et association entre l’hyperhomocystéinémie et le syndrome métabolique

Ferjani

Bouzid

Khiari

et al. 2011

Immuno-analyse & Biologie Spécialisée

View full text Add to dashboard Cite

Dosage de l'homocystéine totale chez une cohorte de diabétiques de type 2

Cited by 4 publications

References 15 publications

Effect of lipopenic and hypotensive treatment on homocysteine levels in type 2 diabetics

Effect of lipopenic and hypotensive treatment on homocysteine levels in type 2 diabetics

Hyperhomocysteinemia: Risk Factors and Faster Onset of Degenerative Complications of Type 2 Diabetes in Brazzaville

Relation entre l’homocystéine et la créatinine sanguines chez des sujets atteints de syndrome métabolique et association entre l’hyperhomocystéinémie et le syndrome métabolique

Contact Info

Product

Resources

About